Sign In
Buy PHAT
$10.09
+0.440 (+4.56%)
At Close: Jun 03, 2026
FLORHAM PARK, N.J., Oct. 30, 2023 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastroint
Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences
08:01am, Wednesday, 25'th Oct 2023
FLORHAM PARK, N.J., Oct. 25, 2023 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastroint
NEW YORK , Oct. 23, 2023 /PRNewswire/ -- Levi & Korsinsky announces that it has commenced an investigation of Phantom Pharmaceuticals, Inc. (NASDAQ: PHAT) concerning possible breaches of fiduciary dut
Following Up On Phathom Pharmaceuticals
12:43pm, Thursday, 05'th Oct 2023
Phathom Pharmaceuticals is a small biopharma firm focused on developing treatments for gastrointestinal diseases. The company has recently filed some marketing applications around its primary drug can
Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences
08:00am, Tuesday, 05'th Sep 2023
FLORHAM PARK, N.J., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastroin
3 Cheap Biotech Stocks That Smart Investors Will Snap Up Now
02:34pm, Monday, 07'th Aug 2023
One of the safest sectors on the market is biotech. After all, we can't stop people from aging — at least not yet.
Phathom Pharma: Time To Take Profits (Rating Downgrade)
04:12pm, Friday, 14'th Jul 2023
Phathom Pharmaceuticals, Inc. is trading near 52-week highs. Despite its potential, there are reasons, like a competitive market, why we should take profits on Phathom Pharmaceuticals. If it falls bac
3 Top Breakout Stocks Worth a Buy for Attractive Returns
10:08am, Friday, 07'th Jul 2023
Phathom Pharmaceuticals (PHAT), Universal Stainless & Alloy Products (USAP) and Arlo Technologies (ARLO) are the breakout picks for today.
Does Phathom Pharmaceuticals, Inc. (PHAT) Have the Potential to Rally 81.38% as Wall Street Analysts Expect?
11:05am, Thursday, 01'st Jun 2023
The mean of analysts' price targets for Phathom Pharmaceuticals, Inc. (PHAT) points to an 81.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong a
Phathom Pharmaceuticals, Inc. (PHAT) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
11:05am, Friday, 26'th May 2023
Phathom Pharmaceuticals, Inc. (PHAT) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong
Should You Buy Phathom Pharmaceuticals, Inc. (PHAT) After Golden Cross?
11:01am, Thursday, 25'th May 2023
Phathom Pharmaceuticals, Inc. (PHAT) reached a significant support level, and could be a good pick for investors from a technical perspective. Recently, PHAT's 50-day simple moving average broke out a
Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences
08:00am, Wednesday, 12'th Apr 2023
FLORHAM PARK, N.J., April 12, 2023 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastroin
Phathom (PHAT) Up 8% on Erosive Esophagitis Drug's CRL Update
09:54am, Wednesday, 05'th Apr 2023
Phathom Pharmaceuticals (PHAT) announces a regulatory update regarding vonoprazan for the treatment of erosive esophagitis and H. pylori infection.
Here's Why Phathom Pharmaceuticals, Inc. (PHAT) Is a Great 'Buy the Bottom' Stock Now
11:26am, Monday, 27'th Mar 2023
Phathom Pharmaceuticals, Inc. (PHAT) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong
All You Need to Know About Phathom Pharmaceuticals, Inc. (PHAT) Rating Upgrade to Buy
01:32pm, Tuesday, 07'th Mar 2023
Phathom Pharmaceuticals, Inc. (PHAT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
